GlassScriptPhysician profile
Alexandra Barlow
NPI 1003659103
$4,513.57
in general payments reported to CMS, 2019-2025
27 companies · $3,464 in 2025
The $3,464 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,049 · 2025: $3,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,459 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.58 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $730.44 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $482.83 | 2024-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $414.64 | 2024-2025 | Acthar |
| Abbvie INC. | $384.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $336.84 | 2024-2025 | Saphnelo, Breztri, Tezspire |
| Amgen INC. | $327.61 | 2024-2025 | Tavneos, Otezla, Krystexxa |
| Ani Pharmaceuticals, INC. | $224.61 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $187.01 | 2024-2025 | |
| Lilly USA, LLC | $130.73 | 2024 | Taltz |
| Corcept Therapeutics | $113.35 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $108.28 | 2024-2025 | Benlysta |
| Axsome Therapeutics, INC. | $97.61 | 2025 | Auvelity |
| Fresenius Kabi USA, LLC | $96.87 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Aurinia Pharma U.S., INC. | $88.77 | 2024-2025 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $87.17 | 2025 | Epclusa |
| Novartis Pharmaceuticals Corporation | $85.29 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $84.81 | 2025 | Tremfya |
| Eisai INC. | $84.38 | 2025 | |
| Abiomed | $82.00 | 2025 | |
| Radius Health, INC. | $53.19 | 2024 | Tymlos |
| Organon LLC | $52.25 | 2024-2025 | Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $43.76 | 2025 | Orencia |
| Ars Pharmaceuticals Operations, INC. | $42.69 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $39.96 | 2025 | Dupixent |
| Genentech USA, INC. | $21.60 | 2024 | Actemra |
| Almatica Pharma LLC | $16.26 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.